Back to Ask the Diabetes Team Ask the Diabetes Team

From Bellevue, Washington, USA:

My 46 year old husband has had type 1 diabetes for 21 years and is on Lente twice a day. We are fortunate in that he has never had to go to the hospital or had any complications even though he rarely checks his blood sugar and just relies on how he "feels" to monitor himself. He knows this isn't best since his A1c usually runs around 8.3% (range 4.2-5.8). At his yearly check-up, his doctor recommended that he try Avandia to see if it would help with keeping his sugars lower and improve his A1c and prescribed it. He will check liver tests and another A1c in a month.

In my research, it seems that Avandia isn't really for my husband's case, and the chance that it will help is really remote. It is worth the chance of possible side-effects, even if only used for a month?


Avandia [rosiglitazone] is primarily a drug for patients with type 2 diabetes. It is not a primary drug for the treatment of type 1 diabetes. I would encourage your husband to begin monitoring and improve his insulin therapy as the treatment of choice.


[Editor's comment: If your husband is not currently seeing a diabetes team, I would strongly recommend that he ask for a referral to one. SS]

Original posting 8 Jun 2001
Posted to Pills for Diabetes


  Back to Ask the Diabetes Team Return to the Top of This Page

Last Updated: Tuesday April 06, 2010 15:09:22
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.